Evidence map›Paper›PMID 31199457›Full record

ArticleThe Journal of infectious diseases2019

Compartmentalization of a Multidrug-Resistant Cytomegalovirus UL54 Mutant in a Stem Cell Transplant Recipient with Encephalitis.

Jocelyne Piret, Manuel Schibler, Van Dung Pham, Sébastien Hantz, Federica Giannotti, Stavroula Masouridi-Levrat, Laurent Kaiser, Nathalie Goyette, Sophie Alain, Rong Shi and 1 more

Open access · greenAbstract readCase Reports
In one paragraph

Article in The Journal of infectious diseases, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Practical updates in clinical antiviral resistance testing.Journal of clinical microbiology · 2024
    Review
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 3 countries.

Jocelyne PiretCentre de recherche en infectiologie, CHU de Québec-Université Laval.
Manuel SchiblerLaboratory of Virology and Infectious Diseases Division, Geneva, Switzerland.
Van Dung PhamInstitut de Biologie Intégrative et des Systèmes, Université Laval.
Sébastien HantzINSERM, CHU Limoges, RESINFIT, Université de Limoges.
Federica GiannottiHematology Division, Geneva University Hospitals, Geneva, Switzerland.
Stavroula Masouridi-LevratHematology Division, Geneva University Hospitals, Geneva, Switzerland.
Laurent KaiserLaboratory of Virology and Infectious Diseases Division, Geneva, Switzerland.
Nathalie GoyetteCentre de recherche en infectiologie, CHU de Québec-Université Laval.
Sophie AlainINSERM, CHU Limoges, RESINFIT, Université de Limoges.
Rong ShiInstitut de Biologie Intégrative et des Systèmes, Université Laval.
Guy BoivinCentre de recherche en infectiologie, CHU de Québec-Université Laval.
Université Laval · CACentre Hospitalier Universitaire de Limoges · FRUniversity Hospital of Geneva · CH

Funding

CIHR 148361
6 · The paper itself

Abstract

We report a case of cytomegalovirus encephalitis in a hematopoietic stem cell transplant recipient. A previously uncharacterized V787E mutation in UL54 was identified in cerebrospinal fluid but not plasma specimens. For the V787E recombinant virus, the half maximal effective concentrations for ganciclovir, foscarnet, and cidofovir were 8.6-, 3.4- and 2.9-fold higher than for wild-type virus, and the replicative capacity was lower. The introduction of a bulkier and negatively charged glutamate residue at position 787 could destabilize the finger domain of UL54 DNA polymerase. Viral genotyping of cerebrospinal fluid is warranted in subjects with cytomegalovirus encephalitis, owing to the low penetration of antivirals in this compartment.

Indexed as

AcyclovirAntibiotic ProphylaxisAntiviral AgentsCerebrospinal FluidCytomegalovirusCytomegalovirus InfectionsDrug Resistance, Multiple, ViralEncephalitis, ViralFemaleGraft RejectionHematopoietic Stem Cell TransplantationHumansImmediate-Early ProteinsImmunosuppression TherapyMiddle AgedMutationAcyclovirAntiviral AgentsImmediate-Early ProteinsUL54 protein, herpes simplex virus type IIViral Proteinscerebrospinal fluidcompartmentalizationCytomegalovirusdrug resistanceencephalitishematopoietic stem cell transplantationrecombinant phenotypingreplicative capacitythree-dimensional modeling

Identifiers

PMID31199457
PMCPMC6743826
OpenAlexW2951543504

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.